Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lifestance Health (LFST)

LifeStance raises 2024 guidance as Q3 revenue rises 19% to $312.7 million

Positive Impact 4 of 5 earnings Written later

LifeStance Health Group reported third-quarter 2024 revenue of $312.7 million, up 19% from a year earlier, and a net loss of $6.0 million, down from $61.6 million. The company raised its full-year 2024 revenue, Center Margin and Adjusted EBITDA expectations, which gives shareholders a higher outlook than before the report.

Key points

  • Q3 2024 revenue was $312.7 million, up 19%; Adjusted EBITDA was $30.7 million, up 110%
  • Net loss narrowed to $6.0 million from $61.6 million in Q3 2023
  • Full-year 2024 revenue guidance raised to $1.228 billion to $1.248 billion; Adjusted EBITDA guidance raised to $105 million to $115 million
  • Company continues to expect positive Free Cash Flow for full-year 2024

The filing

CompanyLifestance Health (LFST)
Form8-K, current report
Filed with the SECNov 6, 2024, 6:34 PM ET
Accession number0000950170-24-122575

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.